Abstract
The rate of MRD clearance in AML with standard consolidation chemotherapy is not well defined. A multi-institution retrospective analysis was performed on 107 consecutively treated AML patients in morphologic complete remission with detectable MRD post-induction therapy who received standard chemotherapy consolidation. In response to standard intermediate/high-dose cytarabine consolidation therapy, 26 of 60 patients (43.3%) with MRD threshold of detection of at least 0.1% converted to MRD-negative status (undetectable with assay used), and 6 of 47 patients (12.8%) with MRD threshold of detection > 0.1% converted to MRD-negative status. Multivariable logistic regression for patients with MRD threshold of detection of at least 0.1% showed that, when controlling for age, ELN risk category, dose of cytarabine, and use of a combination agent, treatment with 1 cycle of consolidation cytarabine versus ≥2 cycles decreased the odds of conversion of AML to MRD-negative (OR = 0.24, 95% CI 0.07–0.85, p = 0.03).
Acknowledgments
The authors thank Dr. Jeffrey Gornbein for statistical consultation.
Disclosure statement
C.O has research funding from Stemline, AstraZeneca, Novartis, and Orca Bio. A.S. has research support from BMS; speaker and ad board for Sanofi. A.P. has research funding from Pfizer and Kronos Bio; received honoraria from BMS and AbbVie. D.J. has research funding from Jazz and Pfizer. G.M. has consultancy from Abbvie, Agios, Macrogenics, Pfizer; scientific Advisory Committees Abbvie, Agios, Astellas, BMS/Celgene, Forty Seven, Genentech, Stemline; research Funding: BMS/Celgene, Glycomimetics, Forty Seven/Gilead, Jazz, Astex, Syndax, Immune Onc, Immunogen. A.C.L. has research funding from Amgen, Astellas, Autolus, Kadmon, Kite, Pharmacyclics, Talaris; consulting for Amgen, Abbvie, Actinium, Brisol-Myers Squibb, Pfizer, Sanofi, Takeda. B.A.J has served as a consultant/advisor for AbbVie, BMS, Daiichi Sankyo, Genentech, Gilead, GlycoMimetics, Jazz, Kymera, Pfizer, Rigel, Servier, and Takeda; protocol steering committee for GlycoMimetics; data monitoring committee for Gilead; travel reimbursement/support from AbbVie and Rigel; institutional research funding from AbbVie, Amgen, Aptose, AROG, BMS, Celgene, Daiichi Sankyo, F. Hoffmann-La Roche, Forma, Forty-Seven, Genentech/Roche, Gilead, GlycoMimetics, Hanmi, Immune-Onc, Incyte, Jazz, Loxo Oncology, Pfizer, Pharmacyclics, Sigma Tau, and Treadwell. G.S. has grants from AbbVie, Actinium, Actuate, Agios, Arog, Astellas,Amgen Aptevo, AltruBio, AVM Bio, BMS/Celgene, Biopath, BioMea, Biosight, Cellularity, Celator, Constellation, Cogent, Cellectis, Daiichi-Sankyo, Deciphera, Delta-Fly, Fate, Forma, FujiFilm, Gamida, Genentech-Roche, Glycomimetics, Geron, Gilead, Incyte, Karyopharm, Kiadis, Kite/Gilead, Kronos Bio, Kura, Janssen, Immunogene, Loxo, Marker, Mateon, Onconova, Pfizer, PrECOG, Regimmune, Samus, Sangamo, Sellas, Stemline, Syros, Takeda, Tolero, Trovagene, Agios, Amgen, Jazz, Orca, Ono-UK, Novartis; consultant to BMS, Curios and Daiichi; received honoraria from AstraZeneca; board/advisory committee member for Agios, Gamida, Gilead, Incyte, Amgen, BMS, Novartis, Ono Pharma, AVM Biotech, GSK and AZ; holds stock in Amgen, BMS, and Janssen/J&J.
Correction Statement
This article has been corrected with minor changes. These changes do not impact the academic content of the article.